Heather Bresch, the CEO of Mylan which makes the EpiPen is grilled by House members on why the price of the device has risen to about $600.

The price of the device, used in emergencies to treat severe allergic reactions, has increased more than 500% since Mylan acquired it in 2007. A two-pack of the EpiPen now has a list price of $608.

Rep. Jason Chaffetz asked a simple question to start: You raised the price — what did you think was going to happen?

Bresch did a lot of gymnastics to explain how Mylan actually doesn’t make that much money on the drug, but Chaffetz wasn’t having it.

“This doesn’t make any sense,” he said. “This is why we don’t believe you.”